Avenue Therapeutics to Present BAER-101 Preclinical Data at
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure...
Source: globenewswire.com
Baergic Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Baergic Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Baergic Bio Today - Breaking & Trending Today
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting - Fortress Biotech (NASDAQ:FBIO), Avenue Therapeutics (NASDAQ:ATXI)
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
Source: benzinga.com
New drug shows promise for epilepsy patients with resistant seizures
In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.
Source: news-medical.net
New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients
NEW YORK, Oct. 9, 2023 /PRNewswire/ -- In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure freque...
Source: businessinsider.com
Generic Central Nervous System Drugs Global Market Report 2023: Major Players Include Otsuka Pharmaceutical, Astra Zeneca, Shire, Novartis and Teva Pharmaceutical Industries
/PRNewswire/ -- The "Generic Central Nervous System Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report...
Source: prnewswire.com